SCI & TECH● LOW1h ago · Sep 11, 2026, 12:59 PM
Exelixis zanzalintinib NDA review extended three months by FDA
Seeking Alpha Tech · north america
The FDA has extended its review period for Exelixis' zanzalintinib NDA by three months. This indicates a longer assessment timeframe for the new drug application.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH11m agoUse AI to your advantage with this 4-session courseLa Silla VacíaSCI & TECH15m agoInfinix GT 50 Pro set to make Nigerian debut at PMNC Nigeria Finals, 12 SeptPremium TimesSCI & TECH41m agoAkpata charges law students against over dependence on AIVanguard NigeriaSCI & TECH51m agoRussia rolls out long-delayed 5G, but not for iPhonesVanguard Nigeria